期刊文献+

替格瑞洛对于急性冠状动脉综合征治疗的应用研究 被引量:1

Application of Ticagrelor for the Treatment of Acute Coronary Syndrome
下载PDF
导出
摘要 目的观察和探讨替格瑞洛治疗急性冠状动脉综合征的临床疗效。方法选择烟台山医院2015年4月—2016年3月经皮冠状动脉介入术治疗的ACS患者37例随机分为两组,观察组19例口服替格瑞洛,对照组18例口服氯吡格雷,观察两组患者手术前及术后24 h血小板抑制率、肌红蛋白、血肌酐、心肌肌钙蛋白、肌酸激酶同工酶-MB水平。结果术后观察组患者血小板抑制率为(76.2±7.9)%,肌红蛋白水平(16.2±3.6)μg/L、血肌酐水平(117.8±19.5)μmol/L,与对照组相比差异有统计学意义(P<0.05);心肌肌钙蛋白水平和肌酸激酶同工酶-MB水平与对照组比较差异无统计学意义(P>0.05)。结论经皮冠状动脉介入术治疗同时应用替格瑞洛抗血小板聚集、缓解心肌损伤作用较氯吡格雷更为显著。 Objective To observe and explore the clinical effect of ticagrelor in the treatment of acute coronary syn- drome. Methods Choose from April 2015 to March 2016 percutaneous coronary interention period treatment of 37 pa- tients from Yantaishan Hospital with ACS were randomly divided into two groups, in which observation group:19 cases of treated with oral ticagrelor,and control group of 18 cases treated withclopidogrel. Surgery patients were observed be- fore and after 24 h platelet inhibition rate, myoglobin, creatinine, cardiac troponin, creatine kinase-MB levels. Results The platelet inhibition rate (76.2±7.9)%, myoglobin levels (16.2±3.6)μg/L, serum creatininc level (117.8±19.5)μmol/L, compared with the control group, the difference was significant(P〈0.05);while in cardiac troponin levels and creatine kinase-MB levels ,there is no significant difference (P〉0.05). Conclusion Percutaneous coronary intervention therapy while application with ticagrelor anti-platelet aggregation, relieve myocardial injury, compared with clopidogrel is more significant.
作者 李江华 刘万卉 LI Jiang-hua LIU Wan-hui(Pharmaceutical School, Yantai Univercity , Yantai ,Shandong Province, 264000 Chin)
机构地区 烟台大学药学院
出处 《系统医学》 2017年第2期121-123,共3页 Systems Medicine
关键词 替格瑞洛 急性冠状动脉综合征 抗血小板聚集 Ticagrelor Acute coronary syndrome Anti-platelet aggregation
  • 相关文献

参考文献10

二级参考文献165

  • 1谭大伟,朱平,李小鹰.氯吡格雷抑制血小板功能的两种检测方法比较:血小板聚集实验与血小板膜糖蛋白检测[J].中国组织工程研究与临床康复,2007,11(11):2021-2024. 被引量:11
  • 2Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.- The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J,2011,32(23) : 2999-3054.
  • 3Arora RR, Rai F. Antiplatelet intervention in acute coronary syndrome[J]. Am J Ther, 2009, 16 (5) : e29-e40.
  • 4Wiviott SD, Braunwald E, McCabe CH, et al. Pra- sugrel versus clopidogrel in patients with acute cor- onary syndromes[J]. N Engl J Med, 2007,357 (20) : 2001-2015.
  • 5Husted S, van Giezen JJ. Ticagrelor: the first re- versibly binding oral P2Y12 receptor antagonist [J]. Cardiovasc Ther,2009,27(4) : 259-274.
  • 6Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J]. N Engl J Med,2009,361(11) : 1045- 1057.
  • 7Brilinta (ticagrelor) Tablets: A P2Y(12) platelet inhibitor indicated to reduce the rate of thromboticcardiovascular events in patients with acute coro- nary syndrome (ACS)[J]. P T, 2012,37(4 section 2) : 4-18.
  • 8Teng R, Butler K. Pharmacokinetics, pharmacody- namics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y (12) receptor antagonist, in healthy subjects[J]. Eur J Clin Pharmacol,2010,66(5) : 487-496.
  • 9Teng R, Oliver S, Hayes MA, et al. Absorption, distribution, metabolism, and excretion of ti- cagrelor in healthy subjects[J] Drug Metab Dispos, 2010,38(9) : 1514-1521.
  • 10Storey RF, Husted S, Harrington RA, et al. Inhi- bition of platelet aggregation by AZD6140, a re- versible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes[J]. J Am Coll Cardiol, 2007,50 (19) : 1852-1856.

共引文献382

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部